Appointments, Positive Data Results, and New Product Innovations - Analyst Notes on Thermo Fisher Scientific, Boston Scientific, BD, DENTSPLY, and CareFusion

NEW YORK, April 8, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Thermo Fisher Scientific Inc. (NYSE: TMO), Boston Scientific Corporation (NYSE: BSX), Becton, Dickinson and Co. (NYSE: BDX), DENTSPLY International Inc. (NASDAQ: XRAY), and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Thermo Fisher Scientific Inc. Analyst Notes 

On April 2, 2014, Thermo Fisher Scientific Inc.'s (Thermo Fisher Scientific) stock increased by 0.26%  to end trading at $122.20 per share. Thermo Fisher Scientific's shares jumped 9.47% over the last three months of trading, significantly outperforming the S&P 500 which gained 2.29% during the same period. The full analyst notes on Thermo Fisher Scientific Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04072014/TMO/report.pdf

--

Boston Scientific Corporation Analyst Notes 

On April 1, 2014, Boston Scientific Corporation (Boston Scientific) announced that real-world data on its S-ICD (Subcutaneous Implantable Defibrillator) System was presented online in the European Heart Journal. According to Boston Scientific, the interim analysis of the ongoing EFFORTLESS S-ICD registry (a post-market observational, non-randomized study), which evaluated 456 patients with a mean follow-up of 558 days, is the first real world study to date and confirms the clinical benefits of the S-ICD System in a broad range of patients at risk of sudden cardiac arrest. The Company claims that the S-ICD System provides protection for patients at risk of sudden cardiac arrest without touching the heart. "The EFFORTLESS registry publication provides even more supportive evidence for this innovative therapy. These long-term results in a large patient cohort are comparable to similar data for transvenous ICDs and should help physicians as they decide which patients are the best candidates for the S-ICD System," said Kenneth Stein, M.D., Chief Medical Officer, Rhythm Management, Boston Scientific. The full analyst notes on Boston Scientific Corporation are available to download free of charge at:

http://www.AnalystsReview.com/04072014/BSX/report.pdf

--

Becton, Dickinson and Co. Analyst Notes 

On March 24, 2014, Becton, Dickinson and Co. (BD) announced that Dr. Claire Pomeroy has been elected to the Company's Board of Directors. Commenting on this new Board addition, Vincent A. Forlenza, BD Chairman, CEO and President, remarked, "Dr. Pomeroy's passion for public health, research and healthcare policy, along with her breadth and depth of experience, will undoubtedly bring a valuable perspective to the Company. It is an honor to welcome her to the BD Board of Directors as we advance and evolve our strategy and seek to improve healthcare globally." The Company informed that Dr. Pomeroy is an expert in infectious diseases and a long-time advocate for public health and patients, especially those with HIV/AIDS. She is currently President of the Albert and Mary Lasker Foundation, and a member of the Board of Directors of PRIDE Industries and the Sierra Health Foundation. Dr. Pomeroy also serves as a member of the board of governors for the Foundation for Biomedical Research and the board of trustees for Morehouse School of Medicine. The full analyst notes on Becton, Dickinson and Co. are available to download free of charge at:

http://www.AnalystsReview.com/04072014/BDX/report.pdf

--

DENTSPLY International Inc. Analyst Notes 

On April 2, 2014, shares of DENTSPLY International Inc. (DENTSPLY) gained 1.38% to close at $47.65. Over the past month of trading, shares of DENSTPLY gained 5.00%. In comparison, the broader benchmark index Nasdaq Composite fell 0.73% during that same period. The full analyst notes on DENTSPLY International Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04072014/XRAY/report.pdf

--

CareFusion Corporation Analyst Notes 

On April 1, 2014, CareFusion Corporation (CareFusion) introduced a hair removal system from Surgical Site Solutions - ClipVac® - designed exclusively for a new innovative clipper handle from CareFusion. "This exclusive ClipVac system design from Surgical Site Solutions continues to differentiate our surgical clippers in the industry," said Jan Creidenberg, Vice President and General Manager of Infection Prevention at CareFusion. "The combination of our innovative new clippers and the ClipVac system promotes best practices for hair removal prior to surgery." According to CareFusion, the ClipVac system connects to CareFusion's new surgical clippers and is designed to improve the current hair removal practice by using vacuum technology to capture hair clippings as the hair is cut at the source. The Company claims that this saves time by capturing an average of 98.5% of the hair and airborne contaminants at the source, reducing the need for a secondary process of clean up. Test data supports vacuum technology as a safe, highly effective and efficient alternative when hair removal is carried out in the surgical or ancillary setting. The full analyst notes on CareFusion Corporation are available to download free of charge at:

http://www.AnalystsReview.com/04072014/CFN/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review